Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
Outline of Final Research Achievements |
In experiments using human intestinal epithelial-like Caco-2 cells, we found a bifidobacteria strain that inhibits the absorption and esterification of cholesterol in the small intestine. The possibility that the pharmacokinetics and pharmacological effects of antihyperlipidemic drugs are changed by coadministration with probiotics was suggested. In addition, the results of pharmacoeconomic analysis showed that the ingestion of probiotic preparations in patients with mild hyperlipidemia is cost-effective.
|